www.pharmtech.com

www.pharmtech.com
Share

www.pharmtech.com

 •  October 16

The pharmaceutical industry is under tremendous pressure to make drug development faster and cheaper. “There is a need for better treatments that show real-world efficacy, but the price has to be acceptable to payers and at the same time offer good returns to the developing company,” says Will Downie, Catalent’s senior vice-president of Global...

www.pharmtech.com

 •  September 20

The enormous cost associated with drug development is one of the biggest challenges for pharmaceutical manufacturers. With an estimated cost of $2.6 billion and more than 10 years (1) to develop and test a drug candidate, the pharmaceutical industry is constantly looking for new efficiencies that will save time, money, research, and resources. One...

www.pharmtech.com

 •  May 3

FDA regulation of drug-biologic-device combination products has been a tricky business, with manufacturers struggling to contend with unfamiliar rules and development strategies for these complex therapies. The rise of personalized medicine and technological advances have led to new types of drug-eluting stents, prefilled syringes, autoinjectors,...

www.pharmtech.com

 •  February 14

As you were browsing http://www.pharmtech.com something about your browser made us think you were a bot. There are a few reasons this might happen: You're a power user moving through this website with super-human speed. You've disabled JavaScript in your web browser. A third-party browser plugin, such as Ghostery or NoScript, is preventing...

www.pharmtech.com

 •  February 13

Manufacturers and FDA officials are pressing for Congressional action on the latest version of the Prescription Drug User Fee Act (PDUFA VI) and highlighting key provisions in the program designed to accelerate drug development and application review. Congressional staffers have set a goal for finalizing user fee reauthorization measures by June,...